Exactech Knee, Hip and Ankle Device Recall

Exactech Joint Device Recall
Knox Boteler – Boteler Richardson Wolfe

(April 6, 2022) Medical device company Exactech, Inc has issued a recall for thousands of devices used in knee, hip, and ankle replacements. The plastic may wear early, leading to implant failure and revision surgery. Now patients who had an Exactech hip, knee or ankle device surgically implanted and experienced an early failure event can file claims against Exactech for compensation.

In a formal announcement February 7, 2022, Exactech directed orthopedic surgeons and facilities to notify patients immediately if their procedures involved the Exactech Ultra-High Molecular Weight Polyethylene (UHMWPE) Knee and Ankle Polyethylene Inserts. The devices fit in between metal components in knee and ankle replacements to cushion joints. When defective, the failing device may result in joint stiffness, pain, and degeneration of bone requiring revision surgery. As an FDA Class II Medical Device Recall, use of the product “may cause temporary or medically reversible adverse health consequences.”

What are Exactech Joint Replacement Systems?

Exactech is a global medical device company based in Gainesville, FL specializing in surgical implants specific to joint replacement surgeries. In 2021, Exactech announced troubling findings with its line of hip, knee, and ankle arthroplasty polyethylene inserts. These systems have been used in more than 150,000 knee, hip, and ankle replacement surgeries since first introduced in 2004.

Why Your Exactech Joint Replacement Could Fail

In its February statement, Exactech said its recall was based on non-conforming packaging that failed to protect the devices from early exposure to oxygen. Vacuum-seal bags were defective, allowing exposure and potential oxidation of the polyethylene liners used in many of Exactech’s hip, knee, and ankle devices. The resulting premature breakdown may lead to a broad range of serious discomfort demanding correction by revision surgery.

What’s the Solution if I Have a Failing Exactech Device?

A failed insert component may begin to degrade, fracture or crack over a short period of time relative to typical implant devices. Joints may become stiff and painful, eventually requiring corrective revision surgery. According to the American Association of Orthopedic Surgeons (AAOS), successful knee and hip replacements last 10-20 years for 90% of patients. Studies involving the Exactech products found a much higher rate of failure.
While revision surgery would be the corrective step, the procedure is typically more complex and lacks the same lifespan as a successful first-time joint replacement. Accumulated trauma, scar tissue and mechanical breakdown of components lead to diminished performance. All to say, revision surgery may be required for function, but is not a guarantee of optimal results. No one should wish for a second knee, hip, or ankle surgery.

Exactech Hip Device Recall

In June 2021, Exactech issued an FDA Class II Medical Device Recall of its Exactech Connexion GXL acetabular polyethylene liners used in hip implants. Although the company referenced “risk of edge-loading and premature prosthesis wear” as a possibility in a certain sub-group of patients with specific implant configurations, studies have shown a broader link between catastrophic early polyethylene wear and the use of the Exactech Connexion GXL liner. These studies found the average length between initial implant and diagnosed hip implant failure to be five years or less.

Exactech Knee and Ankle Recall

In February, 2022, Exactech broadened the recall to several of its knee and ankle systems, again due to concerns that the polyethylene liners lead to accelerated excessive wear, bone loss, and device failure requiring revision surgery. The recalled knee and ankle systems include Optetrak (knee), Optetrak Logic (knee), Truliant (knee), and Vantage (ankle). As with the Exactech Connexion GXL hip liners, the tibial inserts/liners used in these knee and ankle implant systems are exhibiting early polyethylene wear, causing the devices to fail.

What Should I Do if I have an Exactech Implant?

You should have received a formal notice from your orthopedic surgeon or clinic if your surgery involved an Exactech device included in the recall. However, with a recall covering procedures from 2004-2022, don’t rely on the notice alone to determine whether you may be impacted. Your best bet would be to reach out to your treating physician directly. (find out whether your surgeon uses Exactech devices)
Surgeons have been advised to discontinue using the Exactech knee and ankle replacement systems in all patients, and devices returned to the manufacturer. For those who already have one of the recalled systems implanted, the company is advising doctors to maintain a patient index and to closely monitor for signs of potential device failure.
How will you know if you have a problem? Symptoms of an Exactech replacement system failure include:
• Pain
• Stiffness
• Inability to bear weight on joint
• Instability in the knee or ankle
• Grinding noise in joint and/or swelling

If you are experiencing any of these issues, your surgeon will order X-rays to determine whether device insert decay is leading to failure.
If the patient is not experiencing pain, decreased mobility, or other adverse symptoms of implant failure, preemptive surgery to remove the device is not recommended.
Your surgeon will determine whether your failed joint requires surgical removal and replacement.

Exactech Implant Claims

You may be entitled to compensation if you had a recalled Exactech replacement system surgically implanted in your knee or ankle and the insert component of that system failed.
Manufacturers like Exactech have a legal obligation to ensure that their products are safe in their design, manufacture, and packing and that they do not cause harm. Exactech’s recall acknowledges that all knee and ankle replacement products made since 2004 were defective and subject to high failure rates.

Compensation for Need for Second Surgery

Patients who required corrective revision surgery because of a defective Exactech implant can file a claim against the manufacturer and seek compensation. Compensation from a successful claim could include monetary damages for pain and suffering as well as medical expenses incurred out of pocket for surgery or related medical treatment. Damages for lost income may also be awarded.
With the 18-year span of the components recall, it is still best you speak with your treating orthopedic regarding any potential impact on your health

For more information related to this post, please contact Boteler Richardson Wolfe at 251.433.7766 or email us at knox@brwlawyers.com

FDA links Rheumatoid Arthritis Drug XELJANZ® to Serious Medical Conditions

FDA links RA Drug XELJANZ® to Serious Medical Conditions

If you or a loved one took the drug Xeljanz® amd Xeljanz® XR for rheumatoid arthritis, psoriatic arthritis or ulcerative colitis and suffered blood clots, cardiovascular problems or cancer you may have a claim for compensation. FDA safety alerts in 2019 and 2021 warned that Xeljanz® may increase the risk of blood clots, heart problems, death and cancer. [Read more here] In response to these findings, the make of Xeljanz® has recently modified the warnings for users of this drug. If you believe you may have a claim because of blood clots, cardiovascular problems or cancer diagnosed after using the medication Xeljanz® or Xeljanz® XR, please give us a call as soon as possible so that we can review your claim! Call Mat Richardson, Esq. at 251 410-7762 or email, mat@brwlawyers.com or you can talk with any of the lawyers at our firm, Boteler Richardson Wolfe – Injury Lawyers 251 433-7766, to learn more about your potential claim. No charge for consultations and no legal fees unless money is recovered for the client. Lawyers licensed in Florida, Alabama, Georgia and Mississippi.

REQUIRED DISCLAIMERS: Alabama Rule of Professional Conduct 7.2: No representation is made that the quality of legal service to be performed is greater than the services provided by other lawyers. The Mississippi Supreme Court advises that a decision on legal services is important and should not be based solely on advertisements. Free background information is available upon request to a Mississippi attorney. The listing of any area of practice by a Mississippi attorney does not indicate any certification of expertise therein. See Mississippi Rules of Professional Conduct Rule 7.2(d), Rule 7.4(a), Rule 7.6(a) (1997). Statement in compliance with Florida Bar Advertising Rules: “The hiring of a lawyer is an important decision that should not be based solely upon advertisements. Before you decide, ask us to send you free written information about our qualifications and experience. [Florida Rule 4-7.2(d)]. Georgia Rule of Professional Conduct 7.2 requires the physical location of the firm be disclosed: 3290 Dauphin Street, Suite 505, Mobile, AL 36606. General Disclaimer: This information is posted for general information purposes to help those interested parties or persons with potential civil claims better understand their rights and potential causes of action. If readers are currently represented by an attorney on the subject matter of this post then they are encouraged to continue with said representation. No attorney-client relationship is established by this post.

Hyper link for [Read more here] https://www.fda.gov/drugs/drug-safety-and-availability/fda-requires-warnings-about-increased-risk-serious-heart-related-events-cancer-blood-clots-and-death

What’s Up with the Zantac Recall Ads?

What’s Up with the Zantac Recall Ads?

On April 1, 2020, the FDA announced the immediate withdrawal of all prescription and over the counter Ranitidine and Zantac ® from the market. In its announcement, the agency stated that it “determined that the impurity in some ranitidine products increases over time and when stored at higher than room temperatures and may result in consumer exposure to unacceptable levels of this impurity.” The impurity, NDMA, is a known cancer causing chemical. Before April’s announcement, it was thought the impurity formed in the body. While this continues to be a common thought in the scientific community, thzantace FDA cautioned in its announcement that the impurity may result from when the drug is stored for longer periods of time at temperatures above 72 degrees. There are additional studies that will, hopefully, shed light on the reason for the impurity, but, for now, those studies have been delayed due to Covid-19.

According to studies of the contaminant NDMA (N-nitrosodimethylamine), possible side effects of ingestion are:

Bladder Cancer
Colorectal Cancer
Esophageal Cancer
Intestinal Cancer
Kidney Cancer
Liver Cancer
Ovarian Cancer
Pancreatic Cancer
Stomach Cancer
Testicular Cancer
Uterine Cancer

Currently, lawsuits and claims filed throughout the country have been consolidated in the U.S. Federal District Court for the Southern District of Florida through a multi-district litigation (MDL) process. While this litigation is in its infancy, there have been several thousand claims filed with the court through a census program. The utilization of this program is incredibly important as it will assist with determining the cause of the impurity found in ranitidine and Zantac ® and the effect NDMA has on the drug’s users.

Proof of cause and effect will be incredibly important and complex in this litigation as there are several hurdles consumers face in this litigation. For instance, those who were prescribed, generic Ranitidine was prescribed much more often than Zantac. This poses a significant problem as the U.S. Supreme Court has held that state law failure to warn claims against manufacturers of generic drugs are preempted be federal drug regulations. In other words, those consumers taking Ranitidine by prescription, only, are prohibited by law from making a claim against a generic manufacturer under a theory the company failed to warn the drug’s usage may cause cancer. Thus, in those cases, consumers will be forced to show evidence there is a defect in the manufacturing process of the generic manufacturer. Another concern, is proof of usage for those who purchased Ranitidine and Zantac ® over-the-counter. Requesting documents from pharmacy reward programs and/or medical savings accounts (MSA) will be imperative. Last, determining the manufacturer responsible for the consumer’s injury will be tasking; there are over 15 manufacturers of Ranitidine and Zantac ®. In summation, given the widespread usage of Ranitidine and Zantac ® and the complex evidentiary and legal theories that must be overcome by the consumer, this litigation pending in Miami, FL may, very well, take several years to reach a conclusion.

For more information related to this article and Ranitidine and Zantac ® claims, call Knox Boteler at 251-433-7766 or email, Knox@BRWlawyers.com

REQUIRED DISCLAIMERS: Alabama Rule of Professional Conduct 7.2: No representation is made that the quality of legal service to be performed is greater than the services provided by other lawyers. The Mississippi Supreme Court advises that a decision on legal services is important and should not be based solely on advertisements. Free background information is available upon request to a Mississippi attorney. The listing of any area of practice by a Mississippi attorney does not indicate any certification of expertise therein. See Mississippi Rules of Professional Conduct Rule 7.2(d), Rule 7.4(a), Rule 7.6(a) (1997). Statement in compliance with Florida Bar Advertising Rules: “The hiring of a lawyer is an important decision that should not be based solely upon advertisements. Before you decide, ask us to send you free written information about our qualifications and experience. [Florida Rule 4-7.2(d)]. General Disclaimer: This information is posted for general information purposes to help those interested parties or persons with potential civil claims better understand their rights and potential causes of action. If readers are currently represented by an attorney on the subject matter of this post then they are encouraged to continue with said representation. No attorney-client relationship is established by this post.

 

Polygrip Denture Cream

Polygrip Denture Cream’s manufacturer, GlaxoSmithKline, is under investigation for failing to inform users of this product’s potential safety risks. Polygrip Denture Cream contains 38 milligrams of zinc per ounce. Health experts recommend 8 milligrams of zinc per day for women and 11 milligrams for men. Medical studies have found excessive zinc may purge the body of copper, a chemical needed for normal brain and nervous system function. GlaxoSmithKline has announced that it will stop making Polygrip formulas containing zinc. Common side effects related to this product’s health risk include: loss of balance, loss of sensation in hands and feet and anemia. If you have any questions regarding your or a family member’s health and the use of Polygrip, please contact Knox Boteler at 866-975-7766 or email him at knox@bfw-lawyers.com for additional information. To learn more about this situation, click here.